论文部分内容阅读
剑桥及伦敦Ludwig癌瘤研究所伦敦分所所长Karol Sikora、A Munro Neville的文章:现在,应用单克隆抗体诊断和治疗人体疾病已成为许多研究人员的主要目标,一个受限制的因素是要有人的而不是小鼠或大鼠的单克隆抗体。为了尽量减少给予动物异种蛋白所产生的问题,有发生过敏反应、免疫复合物形成的临床表现,以及抗体作用消失的危险性,特别需要用人的单克隆抗体来诊断和治疗病人。
Karol Sikora, A Munro Neville, director of the London and London Ludwig Cancer Institute London: Now, the use of monoclonal antibodies to diagnose and treat human diseases has become a major goal of many researchers, and one of the limiting factors is having someone Rather than mouse or rat monoclonal antibodies. In order to minimize the problems posed by the administration of xenogeneic proteins to animals, the occurrence of allergic reactions, the clinical manifestations of immune complex formation, and the risk of the disappearance of antibody action require the use of human monoclonal antibodies in the diagnosis and treatment of patients.